MeSH D008107 - liver diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008107:Â
Liver diseases
D000081011:Hepatic infarction
0 Companies
0 Drugs
Success rate
D006502:Budd-chiari syndrome
0 Companies
0 Drugs
Success rate
D006504:Hepatic veno-occlusive disease
D006505:Hepatitis
0 Companies
0 Drugs
Success rate
D006527:Hepatolenticular degeneration
D006529:Hepatomegaly
0 Companies
0 Drugs
Success rate
D006530:Hepatorenal syndrome
0 Companies
0 Drugs
Success rate
D006975:Portal hypertension
0 Companies
0 Drugs
Success rate
D008100:Liver abscess
0 Companies
0 Drugs
Success rate
D008103:Liver cirrhosis
D008108:Alcoholic liver diseases
0 Companies
0 Drugs
Success rate
D008109:Parasitic liver diseases
0 Companies
0 Drugs
Success rate
D008113:Liver neoplasms
0 Companies
0 Drugs
Success rate
D010382:Peliosis hepatis
0 Companies
0 Drugs
Success rate
D014386:Hepatic tuberculosis
0 Companies
0 Drugs
Success rate
D015211:Zellweger syndrome
D019896:Alpha 1-antitrypsin deficiency
0 Companies
0 Drugs
Success rate
D020065:Hepatopulmonary syndrome
0 Companies
0 Drugs
Success rate
D020518:Focal nodular hyperplasia
0 Companies
0 Drugs
Success rate
D048550:Hepatic insufficiency
0 Companies
0 Drugs
Success rate
D056486:Chemical and drug induced liver injury
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Fresenius Kabi | Medium chain triglycerides | Smoflipid |  | 2016-07-13 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
14%4/29
Phase 2
40%18/45
Phase 3
11%3/27
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use